Afficher de nouveau l’introduction
EUCTR2012-003056-36
Entrée alternative avec des informations locales supplémentaires: NCT01665144

Study of efficacy, safety and tolerability data for BAF312 compared to placebo in patients with secondary progressive multiple sclerosis followed by extended treatment with open-label BAF312

Base de données : WHO (Importation du 29.11.2020)
Modifié: 29.11.2020
Catégorie de maladie:

Health conditions (Source de données: WHO)

Secondary progressive multiple sclerosis
MedDRA version: 21.1Level: PTClassification code 10063400Term: Secondary progressive multiple sclerosisSystem Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Interventions (Source de données: WHO)


Product Name: Siponimod 2 mg tablet
Product Code: BAF312A
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: Siponimod
CAS Number: 1234627-85-0
Current Sponsor code: BAF312
Other descriptive name: BAF312 hemifumarate
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 2-
Pharmaceutical form of the placebo: Film-coated tablet
Route of administration of the placebo: Oral use

Product Name: Siponimod 1 mg tablet
Product Code: BAF312A
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: Siponimod
CAS Number: 1234627-85-0
Current Sponsor code: BAF312
Other descriptive name: BAF312 hemifumarate
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 1-
Pharmaceutical form of the placebo: Film-coated tablet
Route of administration of the placebo: Oral use

Product Name: Siponimod 0.5 mg tablet
Product Code: BAF312A
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: Siponimod
CAS Number: 1234627-85-0
Current Sponsor code: BAF312
Other descriptive name: BAF312 hemifumarate
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 0.5-
Pharmaceutical form of the placebo: Film-coated tablet
Route of administration of the placebo: Oral use

Product Name: Siponimod 0.25 mg tablet
Product Code: BAF312A
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: Siponimod
CAS Number: 1234627-85-0
Current Sponsor code: BAF312
Other descriptive name: BAF312 hemifumarate
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 0.25-
Pharmaceutical form of the placebo: Film-coated tablet
Route of administration of the placebo: Oral use

Inclusion/Exclusion Criteria (Source de données: WHO)

Inclusion criteria:
Prior history of relapsing remitting MS

Secondary progressive multiple sclerosis (SPMS) defined as progressive increase of disability in at least 6 months

EDSS score of 3.0 to 6.5

No relapse or corticosteroid treatment within 3 months

Other protocol-defined inclusion criteria may apply

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 1530
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion criteria:
Women of child bearing potential must use reliable forms of contraception.

Diagnosis of Macular edema during screening period

Any medically unstable condition determined by investigator

Unable to undergo MRI scans

Hypersensitivity to any study drugs or drugs of similar class

Other protocol-defined exclusion criteria may apply

Plus de données sur l’étude tirée du registre primaire de l’OMS

https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-003056-36

Plus de données sur l’étude tirée de la base de données de l’OMS (ICTRP)

http://apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2012-003056-36-LT

Plus d’informations sur l’étude

Date d’enregistrement de l’étude

29.10.2012

Intégration du premier participant

21.12.2012

Statut de recrutement

Authorised-recruitment may be ongoing or finished

Titre scientifique (Source de données: WHO)

A multicenter, randomized, double-blind, parallel-group, placebo-controlled variable treatment duration study evaluating the efficacy and safety of Siponimod (BAF312) in patients with secondary progressive multiple sclerosis followed by extended treatment with open-label BAF312 - EXPAND

Type d’étude (Source de données: WHO)

Interventional clinical trial of medicinal product

Conception de l’étude (Source de données: WHO)

Controlled: yes
Randomised: yes
Open: no
Single blind: no
Double blind: yes
Parallel group: yes
Cross over: no
Other: no
If controlled, specify comparator, Other Medicinial Product: no
Placebo: yes
Other: no
Number of treatment arms in the trial: 2

Phase (Source de données: WHO)

Human pharmacology (Phase I): noTherapeutic exploratory (Phase II): noTherapeutic confirmatory - (Phase III): yesTherapeutic use (Phase IV): no

Points finaux primaires (Source de données: WHO)

Main Objective: Primary objective (Core part): To demonstrate the efficacy of Siponimod (BAF312) relative to placebo in delaying the time to 3-month confirmed disability progression in patients with secondary progressive multiple sclerosis (SPMS) as measured by expanded disability status scale (EDSS)

;Secondary Objective: First key secondary objective (Core part): To demonstrate the efficacy of Siponimod relative to placebo in delaying the time to 3-month confirmed worsening of at least 20% from Baseline in the timed 25-foot walk test (T25W)
Second key secondary objective (Core part): To demonstrate the efficacy of Siponimod relative to placebo in reducing the increase in T2 lesion volume from Baseline

For further secondary objectives please see protocol

Extension Part: To evaluate the long-term safety, tolerability and efficacy of BAF312
;Primary end point(s): Core part: The delay in time to 3-month confirmed disability progression by Siponimod (BAF312) relative to placebo as measured by expanded disability status scale (EDSS)

Confirmed disability is defined as an increase of score of 1 point in patients with baseline score of 3.0-5.0 and 0.5 point increase with baseline score of 5.5 to 6.5.;Timepoint(s) of evaluation of this end point: baseline, every three months up to the maximum of 3 years

Points finaux secondaires (Source de données: WHO)

Secondary end point(s): Core part: The first key secondary endpoint is the delay in time to 3-month confirmed worsening of at least 20% from Baseline in the timed 25-foot walk test (T25W) by Siponimod (BAF312) compared to placebo.

The second key secondary endpoint is the efficacy of Siponimod (BAF312) relative to placebo in reducing the increase in T2 lesion volume from Baseline.

For further secondary endpoints please see protocol.;Timepoint(s) of evaluation of this end point: 1) baseline, every three months up to the maximum of 3 years
2) baseline, every year up to the maximum of 3 years

Contact pour informations (Source de données: WHO)

Novartis Pharma Services AG

Résultats de l’étude (Source de données: WHO)

Résumé des résultats

A multicenter, randomized, double-blind, parallel-group, placebo-controlled variable treatment duration study evaluating the efficacy and safety of Siponimod (BAF312) in patients with secondary progressive multiple sclerosis followed by extended treatment with open-label BAF312

Lien vers les résultats dans le registre primaire

pas encore d’informations disponibles

Informations sur la disponibilité des données individuelles des participants

pas encore d’informations disponibles

Lieux de réalisation des études

Pays où sont réalisées les études (Source de données: WHO)

Argentina, Australia, Austria, Belgium, Bulgaria, Canada, China, Czech Republic, Czechia, Estonia, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Japan, Latvia, Lithuania, Netherlands, Poland, Portugal, Romania, Russian Federation, Slovakia, Spain, Sweden, Switzerland, Turkey, United Kingdom, United States

Contact pour plus d’informations sur l’étude

Contact pour des informations générales (Source de données: WHO)

Clinical Trial Information Desk
Upes str. 19
Novartis Pharma Services Inc. Representative Office
+3705269 1650
DRA.Lithuania@novartis.com

Contact pour des informations scientifiques (Source de données: WHO)

Clinical Trial Information Desk
Upes str. 19
Novartis Pharma Services Inc. Representative Office
+3705269 1650
DRA.Lithuania@novartis.com

Responsables de l’étude

Promoteur principal (Source de données: WHO)

Novartis Pharma Services AG

Plus de numéros d’identification d’étude

Secondary ID (Source de données: WHO)

CBAF312A2304
NCT01665144
2012-003056-36-HU